ClinicalTrials.gov
public full text
Public Domain
Continuation of Antiarrhythmics Following Ventricular Tachycardia Catheter Ablation
The investigators aim to study if patients that undergo catheter ablation for ventricular tachycardia benefit from continuation of Vaughan-Williams class III antiarrhythmic drugs for 3 months after their ablation.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Catheter Ablation Versus Thoracoscopic Ablation to Patients With Permanent Atrial Fibrillation#1362441
- "Is this sedation?” – a Group Delphi process to define cut-off doses and dosing intervals for potentially sedating drugs in palliative care#483482
- Necessity of Anti-Arrhythmic Medication After Surgical Ablation for Atrial Fibrillation#804848
- Trial of Variable Dialysate Bicarbonate#895479
- Efficacy and Safety of Sirolimus-coated Coronary Balloon Dilatation Catheter for De Novo Coronary Bifurcation Lesions#1282157
Record · ID 1228291
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive